Are Published Health Economic Models for Chronic Hepatitis B Appropriately Capturing the Benefits of HBsAg Loss? A Systematic Literature Review-Reference-Cited by-同舟云学术

Are Published Health Economic Models for Chronic Hepatitis B Appropriately Capturing the Benefits of HBsAg Loss? A Systematic Literature Review

Published:2019-08-19 Issue:3 Volume:4 Page:403-418
ISSN:2509-4262
Container-title:PharmacoEconomics - Open
language:en
Short-container-title:PharmacoEconomics Open

Author:

Wigfield Peter^ORCID,Sbarigia Urbano,Hashim Mahmoud,Vincken Talitha,Heeg Bart

Funder

Janssen Pharmaceutica NV, Belgium

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Health Policy,Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s41669-019-00175-w.pdf

Reference110 articles.

1. Hepatitis B (2018) World Health Organisation (WHO). http://www.who.int/news-room/fact-sheets/detail/hepatitis-b . Accessed 19 Oct 2018

2. EASL (2017) Clinical Practice Guidelines on the management of hepatitis B virus infection. http://www.easl.eu/medias/cpg/management-of-hepatitis-B-virus-infection/English-report.pdf . Accessed 19 Oct 2018

3. EASL (2012) European Association for the Study of the Liver

4. Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. https://www.journal-of-hepatology.eu/article/S0168-8278(12)00167-5/pdf . Accessed 1 Nov 2018

5. WHO (2018) Hepatitis B—Key Facts. World Health Organisation (WHO). http://www.who.int/en/news-room/fact-sheets/detail/hepatitis-b . Accessed 1 Nov 2018

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictors of therapeutic response to peginterferon α‑2a and nucleos(t)ide analog combination therapy for HBeAg‑negative chronic hepatitis B: 1‑year follow‑up after treatment;Experimental and Therapeutic Medicine;2023-11-03

2. Cost-effectiveness of combination antiviral treatment with extended duration for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B in China;Annals of Translational Medicine;2021-09

3. Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements;PharmacoEconomics;2020-01-10